{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-008370","form_type":"8-K/A","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2023-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.582532+00:00","generated_at":"2026-06-17T23:40:29.918573+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TOI amends Q4/FY2022 results: net loss up $1.5M due to goodwill tax adjustment","bullets":["Net loss for Q4 2022 increased by $1.5M; net income for FY2022 decreased by $1.5M due to tax deductible goodwill adjustment.","Updated Q4 revenue $71M (+36.6% YoY), gross profit $16M (+87.6% YoY), net loss $11.0M.","FY2022 ended with $132M cash; added 3 gain share contracts; market count increased to 15.","Management: surpassed top end of revised 2022 guidance for Revenue, Gross Profit, Adjusted EBITDA.","Remediated two material weaknesses; continues plan for complex accounting transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-008370","json":"https://secwatch.observer/filing/0001628280-23-008370.json","markdown":"https://secwatch.observer/filing/0001628280-23-008370.md","text":"https://secwatch.observer/filing/0001628280-23-008370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023008370/0001628280-23-008370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023008370/toi-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:40:29.918573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b24b8ba6abd48fa1f69c9948cc4a71a769c0796","claim":"Oncology Institute, Inc. reported fourth quarter ended December 31, 2022 results: revenue $71 million, net income Net loss of $11.0 million, EPS $(0.12) and $(0.16).","evidence_excerpt":"Fourth Quarter 2022 Financial Highlights • Consolidated revenue of $71 million, an increase of 36.6% from $52 million compared to the prior year quarter • Gross profit of $16 million, an increase of 87.6% compared to the prior year quarter • Net loss of $11.0 million compared to net loss of $10.2 million for the prior year quarter • Basic and diluted earnings per share of $(0.12) and $(0.16), respectively, compared to $(0.13) for the prior year quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023008370/0001628280-23-008370-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$71 million"},{"label":"Net income","value":"Net loss of $11.0 million"},{"label":"EPS","value":"$(0.12) and $(0.16)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}